2025
SJR Q2
JCR Q2 · 4,2
255 eşleşen makale
SCIE
Dergi ayrıntısı
Drug Development Research
- Yayıncı
- John Wiley & Sons Inc.
- Ülke
- United States · Northern America
- Tür
- journal
- ISSN
-
0272439110982299
Bütünleşik değerlendirme
Scopus tarafı Scimago SJR; WoS tarafı Master Journal List + JCR/JIF. Kaynaklar ISSN üzerinden eşleştirilir. WoS / JCR metrikleri yalnızca 1997 ve sonrası yıllar için vardır.
WoS / JCR verileri 1997 ve sonrası içindir.
Scopus
Scopus · Scimago
- SJR 0,765
- Quartile Q2
- H-Index 76
- Atıf/yayın 4,42
- Doküman (3y) 424
- Atıf (3y) 1.911
Clarivate
Web of Science · JCR · 2025
- JCR Q Q2
- JIF 4,2
- 5Y JIF 4,2
- JCI 0,95
WoS indeksleri
- SCIE
Konu sınıflandırması
Kategoriler (SJR)
WoS kategorileri
Yıllık quartile karşılaştırması
Scimago (SJR) tüm yıllar; Clarivate (JCR / JIF / JCI) 1997 ve sonrası. Güncel yıl açık; diğer yıllar kapalıdır.
WoS / JCR verileri 1997 ve sonrası içindir.
| Yıl | SJR Q | JCR Q (1997+) | SJR | JIF (1997+) | 5Y JIF (1997+) | JCI (1997+) | JCI Q (1997+) | H-Index |
|---|---|---|---|---|---|---|---|---|
| 2025 | Q2 | Q2 | 0,765 | 4,2 | 4,2 | 0,95 | Q1 | 76 |
| 2024 | Q2 | Q1 | 0,756 | 4,2 | 3,9 | 0,98 | Q1 | 70 |
| 2023 | Q2 | Q2 | 0,672 | 3,5 | 4 | 0,95 | Q2 | 70 |
| 2022 | Q2 | Q2 | 0,651 | 3,8 | 4 | 1,01 | Q1 | 70 |
| 2021 | Q3 | Q2 | 0,552 | 5 | 4,3 | 1,06 | Q1 | 70 |
| 2020 | Q2 | Q2 | 0,582 | 4,4 | 3,7 | 1,2 | Q1 | 70 |
| 2019 | Q3 | Q4 | 0,483 | 1,9 | 2,2 | 0,7 | Q2 | 70 |
| 2018 | — | Q4 | — | 1,7 | 1,8 | 0,74 | Q2 | — |
| 2017 | Q2 | Q2 | 0,65 | 2,6 | 1,7 | 0,64 | Q3 | 70 |
| 2016 | Q2 | Q3 | 0,522 | 1,9 | 1,2 | — | — | 70 |
| 2015 | Q3 | Q4 | 0,342 | 1 | 0,9 | — | — | 70 |
| 2014 | Q3 | Q4 | 0,311 | 0,8 | 0,9 | — | — | 70 |
| 2013 | Q3 | Q4 | 0,327 | 0,7 | 1 | — | — | 70 |
| 2012 | Q3 | Q4 | 0,358 | 0,9 | 1 | — | — | 70 |
| 2011 | Q3 | Q4 | 0,366 | 1,2 | 1,4 | — | — | 70 |
| 2010 | Q3 | Q3 | 0,374 | 1,1 | 1,2 | — | — | 70 |
| 2009 | — | Q4 | — | 0,7 | 1,1 | — | — | — |
| 2008 | — | Q3 | — | 1,4 | 1 | — | — | — |
| 2007 | — | Q4 | — | 1 | 0,8 | — | — | — |
| 2006 | — | Q4 | — | 0,8 | — | — | — | — |
| 2005 | — | Q4 | — | 0,8 | — | — | — | — |
| 2004 | — | Q4 | — | 0,9 | — | — | — | — |
| 2003 | — | Q3 | — | 1,2 | — | — | — | — |
| 2002 | — | Q3 | — | 1,3 | — | — | — | — |
| 2001 | — | Q3 | — | 1,4 | — | — | — | — |
| 2000 | — | Q2 | — | 1,4 | — | — | — | — |
| 1999 | — | Q2 | — | 1,5 | — | — | — | — |
| 1998 | — | Q2 | — | 1,7 | — | — | — | — |
| 1997 | — | Q1 | — | 2 | — | — | — | — |
JCR kategori quartile geçmişi
Yıla ve kategoriye göre JCR / JCI quartile. 1997 ve sonrası.
WoS / JCR verileri 1997 ve sonrası içindir.
| Yıl | Kategori | Edition | JCR Q (1997+) | JCI Q (1997+) | Sıra |
|---|---|---|---|---|---|
| 2025 | CHEMISTRY, MEDICINAL | SCIE | Q2 | Q2 | 27/72 |
| 2025 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q1 | 102/356 |
| 2024 | CHEMISTRY, MEDICINAL | SCIE | Q2 | Q2 | 23/72 |
| 2024 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q1 | 75/352 |
| 2023 | CHEMISTRY, MEDICINAL | SCIE | Q2 | Q2 | 32/72 |
| 2023 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q2 | 100/354 |
| 2022 | CHEMISTRY, MEDICINAL | SCIE | Q2 | Q2 | 27/60 |
| 2022 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q1 | 105/278 |
| 2021 | CHEMISTRY, MEDICINAL | SCIE | Q2 | Q1 | 19/63 |
| 2021 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q1 | 77/279 |
| 2020 | CHEMISTRY, MEDICINAL | SCIE | Q2 | Q1 | 19/62 |
| 2020 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q1 | 89/276 |
| 2019 | CHEMISTRY, MEDICINAL | SCIE | Q4 | Q3 | 46/61 |
| 2019 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q2 | 203/271 |
| 2018 | CHEMISTRY, MEDICINAL | SCIE | Q4 | Q3 | 47/61 |
| 2018 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | Q2 | 202/267 |
| 2017 | CHEMISTRY, MEDICINAL | SCIE | Q2 | Q3 | 27/59 |
| 2017 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q3 | 124/261 |
| 2016 | CHEMISTRY, MEDICINAL | SCIE | Q3 | — | 43/60 |
| 2016 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 171/257 |
| 2015 | CHEMISTRY, MEDICINAL | SCIE | Q4 | — | 51/59 |
| 2015 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 226/255 |
| 2014 | CHEMISTRY, MEDICINAL | SCIE | Q4 | — | 56/59 |
| 2014 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 225/255 |
| 2013 | CHEMISTRY, MEDICINAL | SCIE | Q4 | — | 55/58 |
| 2013 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 219/256 |
| 2012 | CHEMISTRY, MEDICINAL | SCIE | Q4 | — | 54/59 |
| 2012 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 214/261 |
| 2011 | CHEMISTRY, MEDICINAL | SCIE | Q4 | — | 49/59 |
| 2011 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 198/261 |
| 2010 | CHEMISTRY, MEDICINAL | SCIE | Q3 | — | 39/54 |
| 2010 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 195/252 |
| 2009 | CHEMISTRY, MEDICINAL | SCIE | Q4 | — | 44/46 |
| 2009 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 207/237 |
| 2008 | CHEMISTRY, MEDICINAL | SCIE | Q3 | — | 26/41 |
| 2008 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 159/219 |
| 2007 | CHEMISTRY, MEDICINAL | SCIE | Q4 | — | 33/41 |
| 2007 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 167/205 |
| 2006 | CHEMISTRY, MEDICINAL | SCIE | Q4 | — | 31/35 |
| 2006 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 173/199 |
| 2005 | CHEMISTRY, MEDICINAL | SCIE | Q4 | — | 30/34 |
| 2005 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 167/193 |
| 2004 | CHEMISTRY, MEDICINAL | SCIE | Q4 | — | 28/36 |
| 2004 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 150/187 |
| 2003 | CHEMISTRY, MEDICINAL | SCIE | Q3 | — | 21/37 |
| 2003 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 126/185 |
| 2002 | CHEMISTRY, MEDICINAL | SCIE | Q3 | — | 20/35 |
| 2002 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 107/188 |
| 2001 | CHEMISTRY, MEDICINAL | SCIE | Q3 | — | 20/36 |
| 2001 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 94/186 |
| 2000 | CHEMISTRY, MEDICINAL | SCIE | Q2 | — | 17/35 |
| 2000 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 81/181 |
| 1999 | CHEMISTRY, MEDICINAL | SCIE | Q2 | — | 13/30 |
| 1999 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 67/175 |
| 1998 | CHEMISTRY, MEDICINAL | SCIE | Q2 | — | 11/30 |
| 1998 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 49/178 |
| 1997 | CHEMISTRY, MEDICINAL | SCIE | Q1 | — | 7/28 |
| 1997 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 34/157 |